Skip to content

3D Bioprinted Vascularized Tumour for Drug Testing

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q1Scopus Q1
Citation
Web of Science 85Scopus 92
FWCI (Scopus)
0
JCR IF
JCR 2019 4.556
ISSN
1661-6596

Authors

  1. Han, SeokgyuFirst authorSchool of Mechanical Engineering, Sungkyunkwan University, Suwon, 16419, Korea;
  2. Kim, SeinDepartment of Biomedical Engineering, Sungkyunkwan University, Suwon, 16419, Korea;
  3. Chen, ZhenzhongSchool of Mechanical Engineering, Sungkyunkwan University, Suwon, 16419, Korea;
  4. Shin, Hwa-kyoungDepartment of Korean Medical Science, School of Korean Medicine, Pusan National University, Yangsan, 50612, Korea;
  5. Lee, Seo-YeonDepartment of Pharmacology, School of Medicine, Wonkwang University, Iksan, 54538, Korea;
  6. Moon, Hyo EunDepartment of Neurosurgery, Seoul National University Hospital, Seoul, 03080, Korea;
  7. Paek, Sun HaDepartment of Neurosurgery, Seoul National University Hospital, Seoul, 03080, Korea;
  8. Park, SungsuCorresponding authorSchool of Mechanical Engineering, Sungkyunkwan University, Suwon, 16419, Korea;

Abstract

An in vitro screening system for anti-cancer drugs cannot exactly reflect the efficacy of drugs in vivo, without mimicking the tumour microenvironment (TME), which comprises cancer cells interacting with blood vessels and fibroblasts. Additionally, the tumour size should be controlled to obtain reliable and quantitative drug responses. Herein, we report a bioprinting method for recapitulating the TME with a controllable spheroid size. The TME was constructed by printing a blood vessel layer consisting of fibroblasts and endothelial cells in gelatine, alginate, and fibrinogen, followed by seeding multicellular tumour spheroids (MCTSs) of glioblastoma cells (U87 MG) onto the blood vessel layer. Under MCTSs, sprouts of blood vessels were generated and surrounding MCTSs thereby increasing the spheroid size. The combined treatment involving the anti-cancer drug temozolomide (TMZ) and the angiogenic inhibitor sunitinib was more effective than TMZ alone for MCTSs surrounded by blood vessels, which indicates the feasibility of the TME for in vitro testing of drug efficacy. These results suggest that the bioprinted vascularized tumour is highly useful for understanding tumour biology, as well as for in vitro drug testing.

Keywords

tumour microenvironmentbioprintingblood vesselangiogenesisfibroblastEPITHELIAL-MESENCHYMAL TRANSITIONIN-VITROCANCERANGIOGENESISGLIOBLASTOMAMETASTASISMODEL

Identifiers

Scopus EID
2-s2.0-85083854783
WoS UID
000535565300335